{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28XIFAXAN%29&page=4", "query": { "intervention": "Rifaximin (XIFAXAN)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28XIFAXAN%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin+%28XIFAXAN%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T09:56:56.061Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01842581", "title": "The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatic Encephalopathy", "Cirrhosis" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" }, { "name": "Lactulose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2013-01-08", "completion_date": "2014-12-17", "has_results": true, "last_update_posted_date": "2019-09-09", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Coronado, California • Fresno, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01842581" }, { "nct_id": "NCT01359228", "title": "Rifaximin Treatment of Papulopustular Rosacea", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rosacea" ], "interventions": [ { "name": "Rifaximin (XIFAXAN)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-04", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-04-28", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359228" }, { "nct_id": "NCT03219528", "title": "A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Rifaximin 550 MG", "type": "DRUG" }, { "name": "Low FODMAP Diet", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2018-02-13", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219528" }, { "nct_id": "NCT00328380", "title": "Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diarrhea" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2005-12", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 3, "location_summary": "South Miami, Florida • Houston, Texas • La Porte, Texas", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "La Porte", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00328380" }, { "nct_id": "NCT01842113", "title": "Quality of Life and Nutritional Improvements in Cirrhotic Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cirrhosis", "Hepatic Encephalopathy", "Portal Hypertension" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" }, { "name": "Lactulose", "type": "DRUG" }, { "name": "Lactulose Placebo", "type": "DRUG" }, { "name": "Rifaximin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tampa General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2013-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-23", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01842113" }, { "nct_id": "NCT03515044", "title": "Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Overt Hepatic Encephalopathy" ], "interventions": [ { "name": "40 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "40 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD once daily", "type": "DRUG" }, { "name": "80 mg Rifaximin SSD twice daily", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2018-09-13", "completion_date": "2020-03-12", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 34, "location_summary": "Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more", "locations": [ { "city": "Corona del Mar", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bristol", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03515044" }, { "nct_id": "NCT01542541", "title": "A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intestinal FDG Uptake" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2011-07", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-12-13", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01542541" }, { "nct_id": "NCT00619970", "title": "Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Abdominal Pain", "Small Intestinal Bacterial Overgrowth" ], "interventions": [ { "name": "Lactulose Breath Test", "type": "PROCEDURE" }, { "name": "xifaxan", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Children's Hospital Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "8 Years to 18 Years" }, "enrollment_count": 115, "start_date": "2007-02", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2017-02-16", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00619970" }, { "nct_id": "NCT03729271", "title": "Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Irritable Bowel Syndrome", "Irritable Bowel Syndrome With Diarrhea" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" }, { "name": "Glucose and lactulose hydrogen breath testing", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 148, "start_date": "2020-01-09", "completion_date": "2026-01-01", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03729271" }, { "nct_id": "NCT00577772", "title": "Transit Time and Bacterial Overgrowth Using SmartPill Capsule", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Small Bowel Bacterial Overgrowth", "Gastrointestinal Diseases", "Stomach Diseases", "Digestive System Diseases" ], "interventions": [ { "name": "Xifaxan", "type": "DRUG" }, { "name": "SmartPill", "type": "DEVICE" }, { "name": "Lactulose hydrogen breath test (H_2BT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 17, "start_date": "2007-11", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-10-13T09:56:56.061Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577772" } ] }